Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Gen Comp Endocrinol. 2022 Jun 24;327:114090. doi: 10.1016/j.ygcen.2022.114090

Figure 4.

Figure 4.

Silastic implants allowed for long-term T administration. (A) Average longitudinal weekly (Weeks 0–11) and biweekly (13–21) T levels (ng/mL; mean ± SD) for female C57BL/6N mice implanted with silastic tubing filled with 5 mg T enanthate or a sesame oil vehicle control. Implants were administered under anesthesia and replaced every 7 weeks (weeks 0, 7, 14). T levels were tracked on a weekly or biweekly basis and remained elevated in T-treated mice through the 21 weeks of treatment. (B) Silastic implants with crystalline T provide stable and sustained release with rapid washout. Average longitudinal weekly T levels (ng/mL; mean ± SD). Female Hsd:ICR mice were implanted with silastic tubing filled with 10 mg crystalline T or a blank control implant. Implants were administered and removed under anesthesia. T levels remained elevated through 12 weeks of treatment (solid fill) and promptly dropped to T levels comparable to controls within one week of removal at 6.5 weeks (outline fill). Arrow indicates when implants were removed for 6.5 weeks on T group.